101
|
Rampersaud S, Fang J, Wei Z, Fabijanic K, Silver S, Jaikaran T, Ruiz Y, Houssou M, Yin Z, Zheng S, Hashimoto A, Hoshino A, Lyden D, Mahajan S, Matsui H. The Effect of Cage Shape on Nanoparticle-Based Drug Carriers: Anticancer Drug Release and Efficacy via Receptor Blockade Using Dextran-Coated Iron Oxide Nanocages. NANO LETTERS 2016; 16:7357-7363. [PMID: 27960523 PMCID: PMC5610656 DOI: 10.1021/acs.nanolett.6b02577] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
Although a range of nanoparticles have been developed as drug delivery systems in cancer therapeutics, this approach faces several important challenges concerning nanocarrier circulation, clearance, and penetration. The impact of reducing nanoparticle size on penetration through leaky blood vessels around tumor microenvironments via enhanced permeability and retention (EPR) effect has been extensively examined. Recent research has also investigated the effect of nanoparticle shape on circulation and target binding affinity. However, how nanoparticle shape affects drug release and therapeutic efficacy has not been previously explored. Here, we compared the drug release and efficacy of iron oxide nanoparticles possessing either a cage shape (IO-NCage) or a solid spherical shape (IO-NSP). Riluzole cytotoxicity against metastatic cancer cells was enhanced 3-fold with IO-NCage. The shape of nanoparticles (or nanocages) affected the drug release point and cellular internalization, which in turn influenced drug efficacy. Our study provides evidence that the shape of iron oxide nanoparticles has a significant impact on drug release and efficacy.
Collapse
Affiliation(s)
- Sham Rampersaud
- Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, NY 10065 (USA)
| | - Justin Fang
- Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, NY 10065 (USA)
- Department of Chemistry, The Graduate Center of City University of New York, 365 Fifth Avenue, New York, NY 10016 (USA)
| | - Zengyan Wei
- Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, NY 10065 (USA)
- Department of Chemistry, The Graduate Center of City University of New York, 365 Fifth Avenue, New York, NY 10016 (USA)
| | - Kristina Fabijanic
- Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, NY 10065 (USA)
| | - Stefan Silver
- Department of Medical Laboratory Sciences, Hunter College, City University of New York, 425 East, 25 Street, New York, NY 10010 (USA)
| | - Trisha Jaikaran
- Department of Medical Laboratory Sciences, Hunter College, City University of New York, 425 East, 25 Street, New York, NY 10010 (USA)
| | - Yuleisy Ruiz
- Department of Medical Laboratory Sciences, Hunter College, City University of New York, 425 East, 25 Street, New York, NY 10010 (USA)
| | - Murielle Houssou
- Department of Medical Laboratory Sciences, Hunter College, City University of New York, 425 East, 25 Street, New York, NY 10010 (USA)
| | - Zhiwei Yin
- Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, NY 10065 (USA)
- Department of Chemistry, The Graduate Center of City University of New York, 365 Fifth Avenue, New York, NY 10016 (USA)
| | - Shengping Zheng
- Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, NY 10065 (USA)
- Department of Chemistry, The Graduate Center of City University of New York, 365 Fifth Avenue, New York, NY 10016 (USA)
| | - Ayako Hashimoto
- Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021 (USA)
- Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Tokyo 113-8655 (Japan)
| | - Ayuko Hoshino
- Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021 (USA)
| | - David Lyden
- Children’s Cancer and Blood Foundation Laboratories, Departments of Pediatrics, and Cell and Developmental Biology, Drukier Institute for Children’s Health, Meyer Cancer Center, Weill Cornell Medicine, New York, New York 10021 (USA)
| | - Shahana Mahajan
- Department of Medical Laboratory Sciences, Hunter College, City University of New York, 425 East, 25 Street, New York, NY 10010 (USA)
- Brain Mind Research Institute, Weill Cornell Medical College, 413 East 69 Street, New York, NY 10021 (USA)
| | - Hiroshi Matsui
- Department of Chemistry, Hunter College, City University of New York, 695 Park Avenue, New York, NY 10065 (USA)
- Department of Chemistry, The Graduate Center of City University of New York, 365 Fifth Avenue, New York, NY 10016 (USA)
- Department of Biochemistry, Weill Cornell Medical College, 413 East 69th Street, New York, NY 10021 (USA)
| |
Collapse
|
104
|
Teng L, Lei HM, Sun F, An SM, Tang YB, Meng S, Wang CH, Shen Y, Chen HZ, Zhu L. Autocrine glutamatergic transmission for the regulation of embryonal carcinoma stem cells. Oncotarget 2016; 7:49552-49564. [PMID: 27322683 PMCID: PMC5226528 DOI: 10.18632/oncotarget.9973] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2015] [Accepted: 05/30/2016] [Indexed: 12/17/2022] Open
Abstract
Glutamate behaves as the principal excitatory neurotransmitter in the vertebrate central nervous system and recently demonstrates intercellular signaling activities in periphery cancer cells. How the glutamatergic transmission is organized and operated in cancer stem cells remains undefined. We have identified a glutamatergic transmission circuit in embryonal carcinoma stem cells. The circuit is organized and operated in an autocrine mechanism and suppresses the cell proliferation and motility. Biological analyses determined a repertoire of glutamatergic transmission components, glutaminase, vesicular glutamate transporter, glutamate NMDA receptor, and cell membrane excitatory amino-acid transporter, for glutamate biosynthesis, package for secretion, reaction, and reuptake in mouse and human embryonal carcinoma stem cells. The glutamatergic components were also identified in mouse transplanted teratocarcinoma and in human primary teratocarcinoma tissues. Released glutamate acting as the signal was directly quantified by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Genetic and pharmacological abolishment of the endogenously released glutamate-induced tonic activation of the NMDA receptors increased the cell proliferation and motility. The finding suggests that embryonal carcinoma stem cells can be actively regulated by establishing a glutamatergic autocrine/paracrine niche via releasing and responding to the transmitter.
Collapse
Affiliation(s)
- Lin Teng
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.,Present address: Department of Cardiology, The First College of Clinical Medical Sciences, China Three Gorges University, Hubei 443003, China
| | - Hui-Min Lei
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Fan Sun
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.,Department of Pharmacy, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
| | - Shi-Min An
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.,Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China
| | - Ya-Bin Tang
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.,Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China
| | - Shuang Meng
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
| | - Cong-Hui Wang
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.,Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China
| | - Ying Shen
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.,Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China
| | - Hong-Zhuan Chen
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.,Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China
| | - Liang Zhu
- Department of Pharmacology and Chemical Biology, Basic Medicine Faculty of Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.,Shanghai Universities Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China
| |
Collapse
|
105
|
Seebohm G, Piccini I, Strutz-Seebohm N. Paving the Way to Understand Autoantibody-Mediated Epilepsy on the Molecular Level. Front Neurol 2015. [PMID: 26217297 PMCID: PMC4491625 DOI: 10.3389/fneur.2015.00149] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023] Open
Abstract
Correct function of neuronal networks is enabled by a delicate interplay among neurons communicating with each other. One of the keys is the communication at chemical synapses where neurotransmitters like glutamate, GABA, and glycine enable signal transfer over the synaptic cleft. Thereby, the neurotransmitters are released from the presynapse and bind as ligands to specific receptors at the postsynaptic side to allow for modulation of the postsynaptic membrane potentials. The postsynaptic electrical signal, which is highly modulated by voltage-gated ion channels, spreads over the dendritic tree and is thus integrated to allow for generation of action potentials at the axon hillock. This concert of receptors and voltage-gated ion channels depends on correct function of all its components. Misfunction of receptors and/or voltage-gated potassium channels (VGKC) leads to diverse adverse effects in patients. Such malfunctions can be the result of inherited genetic alterations or pharmacological side effects by drugs. Recently, autoantibodies targeting receptor or channel complexes like NMDAR, AMPAR, GABA-receptors, glycine receptors, LGI1 or CASPR2 (previously termed as VGKC-complex antibodies) have been discovered. The presence of specific autoantibodies against these targets associates with severe forms of antibody-mediated encephalitis. Understanding the molecular details of autoantibody actions on receptor and VGKC complexes is highly desirable and may open the path to develop specific therapies to treat humoral autoimmune encephalitis. Here, we summarize the current knowledge and discuss technical approaches to fill the gap of knowledge. These techniques include electrophysiology, biochemical approaches for epitope mapping, and in silico modeling to simulate molecular interactions between autoantibody and its molecular target.
Collapse
Affiliation(s)
- Guiscard Seebohm
- Receptor Structure and Function Group, Department of Cardiovascular Medicine, Institute for Genetics of Heart Diseases (IfGH), University Hospital Münster , Münster , Germany
| | - Ilaria Piccini
- Receptor Structure and Function Group, Department of Cardiovascular Medicine, Institute for Genetics of Heart Diseases (IfGH), University Hospital Münster , Münster , Germany
| | - Nathalie Strutz-Seebohm
- Receptor Structure and Function Group, Department of Cardiovascular Medicine, Institute for Genetics of Heart Diseases (IfGH), University Hospital Münster , Münster , Germany
| |
Collapse
|
106
|
Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs. Cancer Res 2015; 75:1782-8. [PMID: 25855379 DOI: 10.1158/0008-5472.can-14-3745] [Citation(s) in RCA: 334] [Impact Index Per Article: 37.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2014] [Accepted: 01/23/2015] [Indexed: 11/16/2022]
Abstract
Tumor cells have an increased demand for amino acids because of their rapid proliferation rate. In addition to their need in protein synthesis, several amino acids have other roles in supporting cancer growth. There are approximately two-dozen amino acid transporters in humans, and tumor cells must upregulate one or more of these transporters to satisfy their demand for amino acids. If the transporters that specifically serve this purpose in tumor cells are identified, they can be targeted for the development of a brand new class of anticancer drugs; the logical basis of such a strategy would be to starve the tumor cells of an important class of nutrients. To date, four amino acid transporters have been found to be expressed at high levels in cancer: SLC1A5, SLC7A5, SLC7A11, and SLC6A14. Their induction occurs in a cancer type-specific manner with a direct or indirect involvement of the oncogene c-Myc. Further, these transporters are functionally coupled, thus maximizing their ability to promote cancer growth and chemoresistance. Progress has been made in preclinical studies, exploiting these transporters as drug targets in cancer therapy. These transporters also show promise in development of new tumor-imaging probes and in tumor-specific delivery of appropriately designed chemotherapeutic agents.
Collapse
Affiliation(s)
- Yangzom D Bhutia
- Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas
| | - Ellappan Babu
- Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas
| | - Sabarish Ramachandran
- Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas
| | - Vadivel Ganapathy
- Department of Cell Biology and Biochemistry, Texas Tech University Health Sciences Center, Lubbock, Texas.
| |
Collapse
|